HPV-positive oropharyngeal cancer: data may justify new approach.
Peres
Judy
J
D052685:Alphapapillomavirus / Q000276:immunology / Q000302:isolation & purification / Q000472:pathogenicity; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D019496:Cancer Vaccines / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000821:virology; D000068818:Cetuximab; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D018572:Disease-Free Survival; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D009856:Oncogene Proteins, Viral; D009959:Oropharyngeal Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000517:prevention & control / Q000821:virology*; D030361:Papillomavirus Infections / Q000150:complications* / Q000821:virology; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D016032:Randomized Controlled Trials as Topic; D015996:Survival Rate; D014412:Tumor Virus Infections / Q000150:complications* / Q000821:virology; D014481:United States / Q000453:epidemiology; D014486:United States Food and Drug Administration
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D019496:Cancer Vaccines; D009856:Oncogene Proteins, Viral; D000068818:Cetuximab; D002945:Cisplatin